Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test.

Abstract

British Journal of Clinical PharmacologyVolume 40, Issue 4 p. 411-412 Free Access Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test [letter] T Tateishi, T Tateishi Department of Clinical Pharmacology, Flinders University of South Australia, Australia.Search for more papers by this authorSG Graham, SG Graham Department of Clinical Pharmacology, Flinders University of South Australia, Australia.Search for more papers by this authorY Krivoruk, Y Krivoruk Department of Clinical Pharmacology, Flinders University of South Australia, Australia.Search for more papers by this authorAJ Wood, AJ Wood Department of Clinical Pharmacology, Flinders University of South Australia, Australia.Search for more papers by this author T Tateishi, T Tateishi Department of Clinical Pharmacology, Flinders University of South Australia, Australia.Search for more papers by this authorSG Graham, SG Graham Department of Clinical Pharmacology, Flinders University of South Australia, Australia.Search for more papers by this authorY Krivoruk, Y Krivoruk Department of Clinical Pharmacology, Flinders University of South Australia, Australia.Search for more papers by this authorAJ Wood, AJ Wood Department of Clinical Pharmacology, Flinders University of South Australia, Australia.Search for more papers by this author First published: October 1995 https://doi.org/10.1111/j.1365-2125.1995.tb04566.xCitations: 8AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Wallmark B., Lorentzon P., Larsson H. The mechanism of action of omeprazole-a survey of its inhibitory actions in vitro. Scand J Gastroenterol 1985; 20 (suppl. 108): 37– 51. 2 McTavish D., Buckley M-T, Heel RC. Omeprazole; an updated review of its pharmacology and therapeutic use in acid related disorders. Drugs 1991; 42: 138– 170. 3 Andersson T., Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521– 530. 4 Rendic S., Kajfez F., Ruf HH. Characterization of cimetidine, ranitidine, and related structures' interaction with cytochrome P-450. Drug Metab Dispos 1983; 11: 137– 142. 5 Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 543– 545. 6 Unge P., Svedberg L-E, Nordgren A., et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: 521– 530. 7 Andersson T., Andren K., Cederberg C., Edvardsson G., Heggelund A., Lundborg P. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 1990; 39: 51– 54. 8 Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989; 83: 688– 697. 9 Kinirons MT, O'Shea D., Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993; 54: 621– 629. 10 Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21: 195– 212. 11 Guengerich FP. Human cytochrome P450 enzymes. In Cytochrome P450, Second edition, ed PR. Montellano Plenum Press, New York, 1994. 12 Honig PK, Wortham DC, Zamani K., et al. Terfenadineketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513– 1518. 13 Watkins PB, Hamilton TA, Annesley TM, et al. The erythromycin breath test as a predictor of cycloserine blood levels. Clin Pharmacol Ther 1990; 48: 120– 129. 14 Kinirons MT, O'Shea D., Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993; 54: 661– 669. 15 Krivoruk Y., Kinirons MT, Wood AJJ, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: Lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994; 56: 608– 614. 16 Kinirons MT, Krivoruk Y., Wilkinson GR, Wood AJJ. Cytochrome P4503A and the dapsone recovery ratio: Lack of inhibition by ketoconazole. Clin Pharmacol Ther 1995; 57: 186. Citing Literature Volume40, Issue4October 1995Pages 411-412 ReferencesRelatedInformation